163 related articles for article (PubMed ID: 21114608)
1. Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes.
Schroner Z; Javorsky M; Tkacova R; Klimcakova L; Dobrikova M; Habalova V; Kozarova M; Zidzik J; Rudikova M; Tkac I
Diabetes Obes Metab; 2011 Jan; 13(1):89-91. PubMed ID: 21114608
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
[TBL] [Abstract][Full Text] [Related]
3. Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis.
Belsey J; Krishnarajah G
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():1-7. PubMed ID: 18435668
[TBL] [Abstract][Full Text] [Related]
4. Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort study.
Thomsen RW; Baggesen LM; Svensson E; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabetes Obes Metab; 2015 Aug; 17(8):771-80. PubMed ID: 25929277
[TBL] [Abstract][Full Text] [Related]
5. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes.
Matthaei S; Bowering K; Rohwedder K; Sugg J; Parikh S; Johnsson E;
Diabetes Obes Metab; 2015 Nov; 17(11):1075-84. PubMed ID: 26212528
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
Owens DR; Swallow R; Dugi KA; Woerle HJ
Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
Lukashevich V; Del Prato S; Araga M; Kothny W
Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
[TBL] [Abstract][Full Text] [Related]
8. Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus.
Torekov SS; Holst JJ; Ehlers MR
Diabetes Obes Metab; 2014 May; 16(5):451-6. PubMed ID: 24251641
[TBL] [Abstract][Full Text] [Related]
9. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
[TBL] [Abstract][Full Text] [Related]
10. Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (ZODIAC-39).
Schrijnders D; Wever R; Kleefstra N; Houweling ST; van Hateren KJ; de Bock GH; Bilo HJ; Groenier KH; Landman GW
Diabetes Obes Metab; 2016 Oct; 18(10):973-9. PubMed ID: 27265756
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.
Azar ST; Echtay A; Wan Bebakar WM; Al Araj S; Berrah A; Omar M; Mutha A; Tornøe K; Kaltoft MS; Shehadeh N
Diabetes Obes Metab; 2016 Oct; 18(10):1025-33. PubMed ID: 27376711
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial.
Brady EM; Davies MJ; Gray LJ; Saeed MA; Smith D; Hanif W; Khunti K
Diabetes Obes Metab; 2014 Jun; 16(6):527-36. PubMed ID: 24373063
[TBL] [Abstract][Full Text] [Related]
13. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
[TBL] [Abstract][Full Text] [Related]
14. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
Hamann A; Garcia-Puig J; Paul G; Donaldson J; Stewart M
Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):6-13. PubMed ID: 18095238
[TBL] [Abstract][Full Text] [Related]
15. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
Fonseca V; Gill J; Zhou R; Leahy J
Diabetes Obes Metab; 2011 Sep; 13(9):814-22. PubMed ID: 21481127
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
Haering HU; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabetes Res Clin Pract; 2015 Oct; 110(1):82-90. PubMed ID: 26324220
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
Wilding JP; Charpentier G; Hollander P; González-Gálvez G; Mathieu C; Vercruysse F; Usiskin K; Law G; Black S; Canovatchel W; Meininger G
Int J Clin Pract; 2013 Dec; 67(12):1267-82. PubMed ID: 24118688
[TBL] [Abstract][Full Text] [Related]
18. Variation in CDKAL1 gene is associated with therapeutic response to sulphonylureas.
Schroner Z; Javorský M; Halušková J; Klimčáková L; Babjaková E; Fabianová M; Slabá E; Kozárová M; Tkáč I
Physiol Res; 2012; 61(2):177-83. PubMed ID: 22292718
[TBL] [Abstract][Full Text] [Related]
19. Genetic variations in TCF7L2 influence therapeutic response to sulfonylureas in Indian diabetics.
Dhawan D; Padh H
Diabetes Res Clin Pract; 2016 Nov; 121():35-40. PubMed ID: 27639123
[TBL] [Abstract][Full Text] [Related]
20. Glycaemic control and mortality in older people with type 2 diabetes: The Fremantle Diabetes Study Phase II.
Bruce DG; Davis WA; Davis TME
Diabetes Obes Metab; 2018 Dec; 20(12):2852-2859. PubMed ID: 30003670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
